Benzinga

Benzinga

Benzinga

mercoledì, agosto 26

Intellia Therapeutics Inc

NTLANASDAQ
Trade with Public
Trade with Public
$13.14
-0.37-2.74%
Ult. Agg.: Aug 26, 2:58 PM
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Intellia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Intellia Therapeutics (NTLA).

Price Target Range — 10 Quarters

Analyst Consensus — 24 Analysts

2S.Buy
14Buy
5Hold
3Sell
Consensus RatingBuy# Analysts24Avg. Consensus PT$25Upside to Avg. PT+93.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 25, 2026CitizensSilvan TurkcanMaintainedMarket Outperform$30
Aug 7, 2026Evercore ISI GroupJonathan MillerUpgradeIn-Line→Outperform$16→$24
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
Benzinga Newsdesk

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.
Benzinga Newsdesk

This Etsy Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts change ratings for Pentair, Intellia Therapeutics, Etsy, Nutrien, and Ionis Pharmaceuticals. See what other analysts say.
Avi Kapoor

PRO
Wolfe Research Downgrades Intellia Therapeutics to Underperform, Announces $9 Price Target

Wolfe Research analyst Andy Chen downgrades Intellia Therapeutics (NASDAQ:NTLA) from Peer Perform to Underperform and announces $9 price target.
Benzinga Newsdesk

Ionis, AstraZeneca Stumble in ATTR-CM Trial as Rivals Stand to Gain

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome favors existing and next-gen therapies.
Vandana Singh

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $17

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $17.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved